Drug Approval | July 05, 2024
Briefs: Alembic Pharmaceuticals and Relonchem
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Laurus Labs receives EIR from USFDA for API facilities
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Renews GMP certifications for India and Malaysia sites
Subscribe To Our Newsletter & Stay Updated
